Tirzepatide price in Spain in 2026: €207.91 to €446.07 per pen, depending on the dose

In Spain, tirzepatide is sold under the brand name Mounjaro. Pharmacy prices published by several specialist websites show that each pen costs between €207.91 (2.5 mg) and €446.07 (12.5 and 15 mg). Each pen holds four weekly doses, so the price covers about four weeks. It is not covered by public funding in Spain, so you need a doctor's prescription and you pay the full cost yourself.

The price depends mainly on the dose. You don't get to choose the dose when you buy: your doctor decides it based on your situation and how you respond. Below you'll find each strength and its price, the reason the Spanish National Health System doesn't cover it and some points to bear in mind before you work out the numbers.

How much each Mounjaro pen costs

The European Medicines Agency (EMA) summary of product characteristics lists Mounjaro in prefilled KwikPen pens at six different doses. Each pen holds four 0.6 ml injections, one a week, and lasts four weeks. These are the per-pen prices listed by holvia.es, alimmenta.com and benaes.com in 2026:

• 2.5 mg per dose pen: €207.91
• 5 mg per dose pen: €271.35
• 7.5 mg per dose pen: €358.71
• 10 mg per dose pen: €358.71
• 12.5 mg per dose pen: €446.07
• 15 mg per dose pen: €446.07

Two things stand out. First, the price doesn't go up in a straight line: 7.5 mg and 10 mg cost the same, and so do 12.5 mg and 15 mg. Second, because each pen lasts four weeks, its price is roughly what a month of treatment at that dose costs. For a month-by-month breakdown, see how much Mounjaro costs per month in Spain.

A note on these figures: they come from secondary sources that agree with each other, but we haven't been able to check them against Spain's official medicines price list (Nomenclátor). They may differ slightly, and the pharmacy will charge whatever price applies on the day.

Tirzepatide and Mounjaro: the same molecule

Tirzepatide is the active substance, and Mounjaro is the brand name Lilly sells it under. So when people look up the price of tirzepatide in Spain, they're really looking for the price of Mounjaro, which is the product with a published price in Spanish pharmacies. The EMA summary of product characteristics states that the 2.5 mg pen holds a total of 10 mg of tirzepatide in 2.4 ml, split across the four doses.

When it arrived in Spain in June 2024, the newspaper El Español reported a price of up to €358 a month. That matches today's price for the 7.5 mg and 10 mg pens. The higher doses cost more.

Why the Spanish National Health System doesn't pay for tirzepatide

According to Redacción Médica and Merca2, Spain's Interministerial Committee on Medicinal Product Pricing decided in December 2025 that none of the six Mounjaro presentations would be publicly funded, because of their high budget impact. That's why the per-pen price above is what the patient ends up paying in full, with no co-payment scheme.

Some context helps here. In February 2026, Spain cut the price of Ozempic and Rybelsus and, at the same time, held back Mounjaro's inclusion in public funding. You'll often read that Mounjaro also became cheaper in 2026, but only the other two were cut. If you'd like to compare, here is the price of Ozempic in Spain per pen and per month.

What affects how much you end up paying

• The dose. A pen costs anywhere from €207.91 to €446.07, depending on the strength. This has the biggest effect on cost, and your doctor sets it, not your budget.
• How long the treatment lasts. Each pen covers four weeks. The total cost depends on how many months you need, and nobody can tell you that in advance.
• Medical assessment and follow-up. Mounjaro is prescription-only. On top of the pen, you'll pay for the consultation where it's prescribed and for follow-up care afterwards. The cost of these depends on where you go.
• Where it comes from. The prices in this article are pharmacy prices. Tirzepatide sold without a prescription outside a pharmacy for a fraction of the price comes with no guarantee of what it contains.

What happens when you stop also matters. Coming off treatment without a plan often means regaining some of the weight, and that changes the long-term sums. We explain this in regaining weight after stopping treatment.

What we know about how well it works: the SURMOUNT-1 trial

To judge whether a price is worth paying, you need to know what results to expect. The key trial is SURMOUNT-1, published in NEJM in 2022 (Jastreboff et al.). It enrolled 2,539 adults without diabetes who had a BMI of 30 or more, or 27 or more with at least one weight-related complication, and followed them for 72 weeks.

Average weight loss was 15.0% with 5 mg, 19.5% with 10 mg and 20.9% with 15 mg, compared with 3.1% with placebo. At each of those doses, 85%, 89% and 91% of participants respectively lost at least 5% of their body weight, compared with 35% on placebo. On 10 mg and 15 mg, half or more lost 20% or more (50% and 57%), compared with 3% on placebo.

These are averages from a trial with a specific population and a fixed length. They can't predict how any one person will do. The benefits also come with side effects that are worth knowing about. We cover them in Ozempic and Mounjaro side effects and how to manage them.

Key takeaways and where to start

In Spain, tirzepatide costs between €207.91 and €446.07 per four-week pen, depending on the dose. It is not publicly funded, so the patient pays the full price. What you actually spend depends on the dose that's right for you and how long you stay on treatment. You need a medical assessment to know whether this kind of treatment makes sense for you. At AiON, a registered doctor assesses you, prescribes treatment where appropriate and follows you up throughout a medical weight-loss programme. You can check whether you're eligible in a few minutes.